The present disclosure relates to antigen presenting cells and uses thereof for treating sepsis. In some aspects, disclosed herein is an antigen presenting cell, comprising: a lipid-based nanoparticle, comprising: a recombinant polynucleotide, comprising: a first nucleic acid encoding an antimicrobial peptide; a second nucleic acid encoding cathepsin B; and a third nucleic acid encoding a linker; and a vitamin-lipid.

Provided is a screening method for a laminin 511 expression promoter, which takes the expression of laminin 511 as an indicator. Also provided is an agent for improving skin barrier function, elasticity, hydration and inflammation. This agent includes at least one extract selected from among a group consisting of brown algae, red algae and green algae.

Provided is a screening method for a laminin 511 expression promoter, which takes the expression of laminin 511 as an indicator. Also provided is an agent for improving skin barrier function, elasticity, hydration and inflammation. This agent includes at least one extract selected from among a group consisting of brown algae, red algae and green algae.

The present invention relates generally to a method for extracting cannabis-derived proteins from cannabis plant material, including the preparation of samples of extracted cannabis-derived proteins for proteomic analysis and methods for analysing a cannabis plant proteome.

The present invention relates generally to a method for extracting cannabis-derived proteins from cannabis plant material, including the preparation of samples of extracted cannabis-derived proteins for proteomic analysis and methods for analysing a cannabis plant proteome.

The invention described herein relates to methods and compositions for treatment of one or more symptoms of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity) by administration of a pharmaceutical composition comprising one or more Nepenthes enzymes.

The present invention relates to a method for obtaining chitin and/or chitosan from insect cuticles. More particularly, the method according to the present invention comprises a first enzymatic hydrolysis of insect cuticles using at least one endopeptidase, separation from the hydrolysis medium of the hydrolyzed cuticles resulting from the first enzymatic hydrolysis, and a second enzymatic hydrolysis of the hydrolyzed cuticles using at least one endopeptidase, excluding exopeptidase.

The present invention relates to a method for obtaining chitin and/or chitosan from insect cuticles. More particularly, the method according to the present invention comprises a first enzymatic hydrolysis of insect cuticles using at least one endopeptidase, separation from the hydrolysis medium of the hydrolyzed cuticles resulting from the first enzymatic hydrolysis, and a second enzymatic hydrolysis of the hydrolyzed cuticles using at least one endopeptidase, excluding exopeptidase.

Disclosed herein include methods, compositions, and kits suitable for use in detecting the activation level of a signal transducer. In some embodiments, there are provided synthetic protein circuits wherein recruitment of synthetic protein circuit components to an association location upon activation of a signal transducer generates an active effector protein. The effector protein can be configured to carry out a variety of functions when in an active state, such as, for example, inducing cell death. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.

Disclosed herein include methods, compositions, and kits suitable for use in detecting the activation level of a signal transducer. In some embodiments, there are provided synthetic protein circuits wherein recruitment of synthetic protein circuit components to an association location upon activation of a signal transducer generates an active effector protein. The effector protein can be configured to carry out a variety of functions when in an active state, such as, for example, inducing cell death. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.